| Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial E Kyriazopoulou, G Poulakou, H Milionis, S Metallidis, G Adamis, ... Nature medicine 27 (10), 1752-1760, 2021 | 480 | 2021 |
| An open label trial of anakinra to prevent respiratory failure in COVID-19 E Kyriazopoulou, P Panagopoulos, S Metallidis, GN Dalekos, G Poulakou, ... Elife 10, e66125, 2021 | 162 | 2021 |
| Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis E Kyriazopoulou, T Huet, G Cavalli, A Gori, M Kyprianou, P Pickkers, ... The Lancet Rheumatology 3 (10), e690-e697, 2021 | 150 | 2021 |
| ACTIVATE-2: a double-blind randomized trial of BCG vaccination against COVID-19 in individuals at risk M Tsilika, E Taks, K Dolianitis, A Kotsaki, K Leventogiannis, C Damoulari, ... Frontiers in immunology 13, 873067, 2022 | 94 | 2022 |
| Current perspectives on the diagnosis and management of healthcare-associated ventriculitis and meningitis M Karvouniaris, A Brotis, K Tsiakos, E Palli, D Koulenti Infection and Drug Resistance, 697-721, 2022 | 49 | 2022 |
| Early start of oral clarithromycin is associated with better outcome in COVID-19 of moderate severity: the ACHIEVE open-label single-arm trial K Tsiakos, A Tsakiris, G Tsibris, PM Voutsinas, P Panagopoulos, ... Infectious Diseases and Therapy 10 (4), 2333-2351, 2021 | 16 | 2021 |
| Author correction: early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial E Kyriazopoulou, G Poulakou, H Milionis, S Metallidis, G Adamis, ... Nature Medicine 27 (10), 1850-1850, 2021 | 12 | 2021 |
| Clarithromycin for early anti-inflammatory responses in community-acquired pneumonia in Greece (ACCESS): a randomised, double-blind, placebo-controlled trial EJ Giamarellos-Bourboulis, A Siampanos, A Bolanou, S Doulou, ... The Lancet Respiratory Medicine 12 (4), 294-304, 2024 | 11 | 2024 |
| ICU-associated gram-negative bloodstream infection: risk factors affecting the outcome following the emergence of colistin-resistant isolates in a regional Greek hospital M Karvouniaris, G Poulakou, K Tsiakos, M Chatzimichail, P Papamichalis, ... Antibiotics 11 (3), 405, 2022 | 10 | 2022 |
| Influenza vaccination in cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis K Tsiakos, KG Kyriakoulis, A Kollias, IG Kyriakoulis, G Poulakou, ... Journal of Immunotherapy 45 (6), 291-298, 2022 | 8 | 2022 |
| Anakinra to prevent respiratory failure in COVID-19 E Kyriazopoulou, P Panagopoulos, S Metallidis, GN Dalekos, G Poulakou, ... medRxiv, 2020.10. 28.20217455, 2020 | 8 | 2020 |
| Early anakinra treatment for COVID-19 guided by urokinase plasminogen receptor E Kyriazopoulou, G Poulakou, H Milionis, S Metallidis, G Adamis, ... medRxiv, 2021.05. 16.21257283, 2021 | 7 | 2021 |
| Oral clarithromycin in COVID-19 of moderate severity: the ACHIEVE open-label trial using concurrent matched comparators K Tsiakos, A Tsakiris, G Tsibris, P Voutsinas, P Panagopoulos, ... MedRxiv, 2020.12. 22.20248753, 2020 | 6 | 2020 |
| Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial (Sept, 10.1038 … E Kyriazopoulou, G Poulakou, H Milionis, S Metallidis, G Adamis, ... NATURE MEDICINE 27 (10), 1850-1850, 2021 | 2 | 2021 |
| Prolonged SARS-CoV-2 Infection With Common Features in Two Patients Receiving Anti-CD20 Therapy A Papanikolopoulou, V Thimis, E Antonogiannaki, V Rapti, K Tsiakos, ... in vivo 37 (1), 461-467, 2023 | 1 | 2023 |
| Programmed Cell Death Protein 1 Axis Inhibition in Viral Infections: Clinical Data and Therapeutic Opportunities K Tsiakos, N Gavrielatou, IA Vathiotis, L Chatzis, S Chatzis, G Poulakou, ... Vaccines 10 (10), 1673, 2022 | 1 | 2022 |
| Clarithromycin for Early Anti-Inflammatory Responses in Community-Acquired Pneumonia: The ACCESS Randomized Trial E Giamarellos-Bourboulis, A Siampanos, A Bolanou, S Doulou, ... | | 2023 |
| Corrigendum: ACTIVATE-2: A double-blind randomized trial of BCG vaccination against COVID-19 in individuals at risk M Tsilika, E Taks, K Dolianitis, A Kotsaki, K Leventogiannis, C Damoulari, ... Frontiers in Immunology 13, 1018384, 2022 | | 2022 |
| Long Term Immune and Epigenetic Dysregulation Following COVID-19: The Impact of Anti-IL-1 Treatment in the Post-Acute COVID Syndrome C Sidiropoulou, E Giamarellos-Bourboulis, G Poulakou, M Tsilika, ... | | 2022 |
| Primary Sarcoidosis of the Adipose Tissue: A New Variant of Sarcoidosis K Tsiakos, I Zoupas, L Chatzis, I Vamvakaris, G Poulakou, K Syrigos Mayo Clinic Proceedings 97 (7), 1403-1405, 2022 | | 2022 |
SYRIGOS KONSTANTINOS N.NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS, GREECE在 med.uoa.gr 的电子邮件经过验证
